Form 4 for ANTX AN2 Therapeutics, Inc.

Accepted 2024-11-05 00:00:00 ET · period of report 2024-11-04 · accession 0000950170-24-121601 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-11-05	2024-11-04	ANTX	Prior Stephen David	Chief Strategy Off	A - Grant	$0.00	+10.1K	35.3K	+40%	$0
D	2024-11-05	2024-11-04	ANTX	Prior Stephen David	Chief Strategy Off	A - Grant	$0.00	+20.2K	20.2K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-11-04	A	A	10,125	$0.00	35,342	D	—	—	(F1) Represents a grant of Restricted Stock Units ("RSUs"). RSUs vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, subject to the Reporting Person's continuous service as of such date. (F2) Includes a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
2	Derivative	Stock Option (right to buy)	2024-11-04	A	A	20,250	$0.00	20,250	D	$1.08 · — to 2034-11-03	20,250 Common Stock	(F3) The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and becomes exercisable monthly over four years from November 4, 2024 until fully vested and exercisable on November 4, 2028, subject to the Reporting Person's continuous service as of such date.